Accueil > Actualité
Actualite financiere : Actualite bourse

Roche: breakthrough designation for mosunetuzumab

( - Roche announces that mosunetuzumab, its investigational immunotherapy for CD20xCD3 bispecific cancer, has received a breakthrough designation from the US FDA, based on favourable data from a Phase I/Ib study.

This designation, which is intended to accelerate drug development and review, is for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.